Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1302-1307

  Zhou, Fei Fei ^a,b,c   Yan, Min ^a   Guo, Gui Fang ^a,b   Wang, Fang ^a,b   Qiu, Hui Juan ^a,b   Zheng, Fei Meng ^a   Zhang, Yan ^a   Liu, Qiang ^a   Zhu, Xiao Feng ^a   Xia, Liang Ping ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Bcl 2 Bax ratio; Chemosensitivity; eIF4E; Migration; Triple negative breast cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; INITIATION FACTOR 4E; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79959236276     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9630-0     Document Type: Article

References (31)

1. GN Hortobagyi 2005 The global breast cancer burden: variations in epidemiology and survival Clin Breast Cancer 6 391 401
2. CM Perou 2000 Molecular portraits of human breast tumours Nature 406 747 752
3. L Harris 2007 American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312
4. F Boccardo A Rubagotti 2007 Switching to aromatase inhibitors in early breast cancer Lancet 369 533 535
5. I Smith 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36
6. EH Romond 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
7. H Joensuu 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820
8. BP Schneider 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 8010 8018
9. J Kurebayashi 2009 Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics Breast Cancer 16 275 280
10. von der Haar T, Gross JD, Wagner G, McCarthy JE. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol. 2004;11:503-11.
11. TV Pestova CU Hellen 2000 The structure and function of initiation factors in eukaryotic protein synthesis Cell Mol Life Sci 57 651 674
12. A De Benedetti JR Graff 2004 eIF-4E expression and its role in malignancies and metastases Oncogene 23 3189 3199
13. A Flowers 2009 Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome Surgery 146 220 226
14. IB Rosenwald 1995 Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels J Biol Chem 270 21176 21180
15. S Li 2003 Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release J Biol Chem 278 3015 3022
16. JR Graff BW Konicek JH Carter EG Marcusson 2008 Targeting the eukaryotic translation initiation factor 4E for cancer therapy Cancer Res 68 631 634
17. HG Wendel 2004 Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 332 337
18. A Kentsis I Topisirovic B Culjkovic L Shao KL Borden 2004 Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap Proc Natl Acad Sci USA 101 18105 18110
19. NJ Moerke 2007 Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G Cell 128 257 267
20. JR Graff 2007 Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity J Clin Invest 117 2638 2648
21. N Oridate HJ Kim X Xu R Lotan 2005 Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin Cancer Biol Ther 4 318 323
22. BT Hennessy DL Smith PT Ram Y Lu GB Mills 2005 Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 988 1004
23. KA West SS Castillo PA Dennis 2002 Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist Updat 5 234 248
24. BD Li L Liu M Dawson A De Benedetti 1997 Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma Cancer 79 2385 2390
25. Li BD, McDonald JC, Nassar R, De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg. 1998;227:756-756l; discussion 761-753.
26. Byrnes K, et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg. 2006;243:684-90; discussion 691-682.
27. CO Nathan 1997 Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas Oncogene 15 1087 1094
28. B Culjkovic KL Borden 2009 Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer J Oncol 2009 981679
29. A Soni 2008 eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling Mol Cancer Ther 7 1782 1788
30. C Arslan O Dizdar K Altundag 2009 Pharmacotherapy of triple-negative breast cancer Expert Opin Pharmacother 10 2081 2093
31. K Dong 2009 Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells Breast Cancer Res Treat 113 443 456